Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.61 |
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12867524 | 1.00 | PTGS1 (0.61) | PTGS1GSTK1NOD1FOLH1GSR | |
| SCHEMBL9160515 | 1.00 | PTGS1 (0.61) | PTGS1GSTK1NOD1FOLH1GSR | |
| SCHEMBL523606 | 0.96 | PTGS1 (0.62) | PTGS1GSTK1NOD1FOLH1SLC6A5 | |
| SCHEMBL523605 | 0.96 | PTGS1 (0.62) | PTGS1GSTK1NOD1FOLH1SLC6A5 | |
| SCHEMBL12867548 | 0.91 | PTGS1 (0.57) | PTGS1GSTK1NOD1FOLH1GSR | |
| SCHEMBL12867529 | 0.91 | PTGS1 (0.57) | PTGS1GSTK1NOD1FOLH1GSR | |
| SCHEMBL13147757 | 0.91 | NOD1 (0.53) | PTGS1GSTK1NOD1FOLH1GSR | |
| SCHEMBL522417 | 0.91 | NOD1 (0.53) | PTGS1GSTK1NOD1FOLH1GSR | |
| SCHEMBL20179363 | 0.90 | PTGS1 (0.70) | PTGS1GSTK1NOD1FOLH1GSR | |
| SCHEMBL431292 | 0.89 | NOD1 (0.65) | PTGS1GSTK1NOD1FOLH1GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0460189-A4 | PRODUCTION OF BIOLOGICALLY ACTIVE PLATELET-DERIVED GROWTH FACTOR FROM HIGH EXPRESSION HOST CELL SYSTEMS | — | 1993-05-26 | — | — | EP | claimed |
| EP-0460189-A1 | PRODUCTION OF BIOLOGICALLY ACTIVE PLATELET-DERIVED GROWTH FACTOR FROM HIGH EXPRESSION HOST CELL SYSTEMS | AMGEN INC. (US) | 1991-12-11 | — | — | EP | claimed |
| WO-1991008762-A1 | PRODUCTION OF BIOLOGICALLY ACTIVE PLATELET-DERIVED GROWTH FACTOR FROM HIGH EXPRESSION HOST CELL SYSTEMS | AMGEN INC. (US) | 1991-06-27 | — | — | WO | claimed |
| EP-2078033-B1 | ISOTOPICALLY LABELED TRAPPING AGENT AND METHOD FOR IDENTIFYING REACTIVE METABOLITES | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-09 | — | — | EP | disclosed |
| US-7884186-B2 | Such as 6-amino-2-[2-(4-amino-4-carboxy-butyrylamino)-3-mercapto-propionylamino]-hexanoic acid; cytochorme p-450; drug screening; eliminates false positives; mass spectrometry | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-08 | — | — | US | disclosed |
| US-7884186-B2 | Such as 6-amino-2-[2-(4-amino-4-carboxy-butyrylamino)-3-mercapto-propionylamino]-hexanoic acid; cytochorme p-450; drug screening; eliminates false positives; mass spectrometry | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-08 | — | — | US | disclosed |
| EP-2078033-A2 | ISOTOPICALLY LABELED TRAPPING AGENT AND METHOD FOR IDENTIFYING REACTIVE METABOLITES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008042634-A2 | ISOTOPICALLY LABELED TRAPPING AGENT AND METHOD FOR IDENTIFYING REACTIVE METABOLITES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-10 | — | — | WO | disclosed |
| US-20080081349-A1 | ISOTOPICALLY LABELED TRAPPING AGENT AND METHOD FOR IDENTIFYING REACTIVE METABOLITES | JANSSEN PHARMACEUTICA N. V. (BE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081349-A1 | ISOTOPICALLY LABELED TRAPPING AGENT AND METHOD FOR IDENTIFYING REACTIVE METABOLITES | JANSSEN PHARMACEUTICA N. V. (BE) | 2008-04-03 | — | — | US | disclosed |
| US-5428135-A | Production of platelet-derived growth factor B-chain heterodimers from high expression host cell system | AMGEN INC. (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0460189-A4 | PRODUCTION OF BIOLOGICALLY ACTIVE PLATELET-DERIVED GROWTH FACTOR FROM HIGH EXPRESSION HOST CELL SYSTEMS | — | 1993-05-26 | — | — | EP | disclosed |
| EP-0460189-A1 | PRODUCTION OF BIOLOGICALLY ACTIVE PLATELET-DERIVED GROWTH FACTOR FROM HIGH EXPRESSION HOST CELL SYSTEMS | AMGEN INC. (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1991008762-A1 | PRODUCTION OF BIOLOGICALLY ACTIVE PLATELET-DERIVED GROWTH FACTOR FROM HIGH EXPRESSION HOST CELL SYSTEMS | AMGEN INC. (US) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081349-A1 | ISOTOPICALLY LABELED TRAPPING AGENT AND METHOD FOR IDENTIFYING REACTIVE METABOLITES | ABCG2, SAMHD1, NSF | PTGS1 2285/4885GSTK1 938/4885NOD1 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.